Perrigo Growth Trajectory Traverses Manufacturing, Licensing Headwinds
This article was originally published in The Tan Sheet
Executive Summary
Perrigo omitted from its fiscal 2015 guidance revenues from generic guaifenesin expectorants because raw material sourcing has not met manufacturing specifications and continues to hold up production. The firm’s plans for launching store brand OTC nasal corticosteroids also are in limbo.
You may also be interested in...
Drug GMP Investor Alerts in Brief
Pharmaceutical manufacturers alerted investors to manufacturing quality issues that arose in the quarter ending June 30, including: Actavis, Acorda, Perrigo, Impax, Cubist, Aastrom and Amphastar.
Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015
Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.
Martek/Mead Agreement
Martek BioSciences will be the exclusive, worldwide supplier of DHA (docosahexaenoic acid) and ARA (arachidonic acid) to infant formula company Mead Johnson (Enfamil) according to a ten-year supply agreement, the firm announces May 18. The agreement is an expansion and extension of a 25-year license agreement signed in 1992. Martek's blend is the only source of these nutrients currently used in U.S. infant formula. However, Abbott Lab's Ross Products Division's (Similac) tuna oil-derived DHA and fungally-derived ARA was granted Generally Recognized as Safe status for use in infant formula by FDA May 18. Martek does not expect to lose customers to Ross because of the latter's GRAS status, the firm asserts in a same-day release. "The levels of DHA and ARA specified in the notification are significantly lower than levels used in the majority of all term and pre-term infant formula sold in the U.S.," Martek notes...